1 November 2024 false Taxfiler 2024.6 14414289 business:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 14414289 2024-10-31 14414289 2024-11-01 2025-10-31 14414289 business:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 14414289 business:FilletedAccounts 2024-11-01 2025-10-31 14414289 2025-10-31 14414289 business:Director1 2024-11-01 2025-10-31 14414289 business:Director2 2024-11-01 2025-10-31 14414289 business:RegisteredOffice 2024-11-01 2025-10-31 14414289 2024-10-31 14414289 core:WithinOneYear 2025-10-31 14414289 core:WithinOneYear 2024-10-31 14414289 core:ShareCapital core:PreviouslyStatedAmount 2025-10-31 14414289 core:ShareCapital core:PreviouslyStatedAmount 2024-10-31 14414289 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2025-10-31 14414289 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2024-10-31 14414289 core:PreviouslyStatedAmount 2025-10-31 14414289 core:PreviouslyStatedAmount 2024-10-31 14414289 business:SmallEntities 2024-11-01 2025-10-31 14414289 countries:EnglandWales 2024-11-01 2025-10-31 14414289 core:ComputerEquipment 2024-11-01 2025-10-31 14414289 core:ComputerEquipment 2024-10-31 14414289 core:ComputerEquipment 2025-10-31 14414289 2023-11-01 2024-10-31 iso4217:GBP xbrli:pure
Company Registration No. 14414289 (England and Wales)
GX Pharma Limited Unaudited accounts for the year ended 31 October 2025
GX Pharma Limited Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
GX Pharma Limited Company Information for the year ended 31 October 2025
Directors
Stephen Jackson Pauline Evans
Company Number
14414289 (England and Wales)
Registered Office
3a Blue Sky Way Monkton Business Park South Hebburn Tyne and Wear NE31 2EQ England
Accountants
Abacus Accounting (NE) Limited 3a Blue Sky Way Monkton Business Park South Hebburn Tyne and Wear NE31 2EQ
- 3 -
GX Pharma Limited Statement of financial position as at 31 October 2025
2025
2024
Notes
£
£
Fixed assets
Tangible assets
4
436
611
Current assets
Debtors
5
50,854
-
Cash at bank and in hand
13,323
81,774
64,177
81,774
Creditors: amounts falling due within one year
6
(201)
(18,653)
Net current assets
63,976
63,121
Net assets
64,412
63,732
Capital and reserves
Called up share capital
100
100
Profit and loss account
64,312
63,632
Shareholders' funds
64,412
63,732
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 21 January 2026 and were signed on its behalf by
Stephen Jackson Director Company Registration No. 14414289
- 4 -
GX Pharma Limited Notes to the Accounts for the year ended 31 October 2025
1
Statutory information
GX Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 14414289. The registered office is 3a Blue Sky Way, Monkton Business Park South, Hebburn, Tyne and Wear, NE31 2EQ, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
10% straight line
4
Tangible fixed assets
Computer equipment
£
Cost or valuation
At cost
At 1 November 2024
873
At 31 October 2025
873
Depreciation
At 1 November 2024
262
Charge for the year
175
At 31 October 2025
437
Net book value
At 31 October 2025
436
At 31 October 2024
611
- 5 -
GX Pharma Limited Notes to the Accounts for the year ended 31 October 2025
5
Debtors
2025
2024
£
£
Amounts falling due within one year
VAT
612
-
Other debtors
50,242
-
50,854
-
6
Creditors: amounts falling due within one year
2025
2024
£
£
VAT
-
(306)
Trade creditors
-
1,200
Taxes and social security
201
3,179
Accruals
-
14,580
201
18,653
7
Average number of employees
During the year the average number of employees was 2 (2024: 2).
- 6 -